Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 7/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | GALK1 | P51570 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190009 | 0.81 | MAPT (0.49) | MAPTSMN1; SMN2HTTATMLMNA | |
| SCHEMBL1156222 | 0.74 | NR4A2 (0.57) | NR4A2CREBBPMAPTMAP2K1HTT | |
| SCHEMBL30393962 | 0.73 | MAPT (0.65) | MAPTMITFSMN1; SMN2HTTNPC1 | |
| SCHEMBL2879389 | 0.73 | MAPT (0.65) | MAPTMITFSMN1; SMN2HTTNPC1 | |
| SCHEMBL21840821 | 0.70 | NPC1 (0.71) | MAPTMITFSMN1; SMN2HTTLMNA | |
| SCHEMBL8757428 | 0.70 | MAPT (0.69) | MAPTMITFSMN1; SMN2HTTLMNA | |
| SCHEMBL926243 | 0.70 | NR4A2 (0.68) | NR4A2CREBBPMAP2K1HTTLMNA | |
| SCHEMBL1155039 | 0.70 | NR4A2 (0.50) | NR4A2CREBBPMAP2K1SMN1; SMN2HTT | |
| SCHEMBL18190923 | 0.70 | NR4A2 (0.50) | NR4A2CREBBPMAPTMITFMAP2K1 | |
| SCHEMBL31167696 | 0.70 | NR4A2 (0.47) | NR4A2CREBBPMAPTHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036441-A1 | Indole Derivatives With Antitumor Activity | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2009-02-05 | — | — | US | disclosed |
| EP-1835908-A2 | INDOLE DERIVATIVES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006066923-A2 | INDOLE DERIVATIVES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036441-A1 | Indole Derivatives With Antitumor Activity | IDO1, IDO2, INMT | NR4A2 1116/4885CREBBP 979/4885MAPT 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.